Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Nicolau syndrome after administration of glatiramer acetate].
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
The INCAT disability score: A critical analysis of its measurement properties.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Assessment of statistical significance and clinical relevance.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Immunomodulatory effects of Vitamin D in multiple sclerosis.
Rituximab Use in Pediatric Central Demyelinating Disease.
Laquinimod in multiple sclerosis.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
4-aminopyridine toxicity: a case report and review of the literature.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Roche reports positive studies of MabThera given by subcutaneous injection
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.

Pages